Alflutinib mesylate
Alflutinib mesylate (AST2818 mesylate) is an irreversible EGFR tyrosine kinase inhibitor with high selectivity for mutant forms, including the T790M resistance mutation. It is utilized in preclinical oncology research, demonstrating activity in both cellular assays and animal models of non-small cell lung cancer.
Product Specifications
CAS Number
2130958-55-1
Product Name Alternative
Alflutinib Mesylate, Alflutinib mesylate, Alflutinib, AST 2818, AST 2818 Mesylate, AST2818, AST-2818, AST2818 Mesylate, AST2818 mesylate, AST-2818 Mesylate, cancer, NSCLC, inhibit, Inhibitor, HER1, EGFR, Epidermal growth factor receptor, ErbB-1, Furmonertinib, esistant mutation, T790M
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.94% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween-80+45% Saline:1 mg/mL (1.5 mM) ; DMSO:55 mg/mL (82.74 mM)
Smiles
CS (O) (=O) =O.CN (C) CCN (C) c1nc (OCC (F) (F) F) c (Nc2nccc (n2) -c2cn (C) c3ccccc23) cc1NC (=O) C=C
Molecular Formula
C29H35F3N8O5S
Molecular Weight
664.70
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog